Crohn's disease future or investigational therapies

Crohn's disease
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Crohn's Disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Crohn's disease future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Crohn's disease future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Crohn's disease future or investigational therapies
CDC on Crohn's disease future or investigational therapies
Crohn's disease future or investigational therapies in the news
Blogs on Crohn's disease future or investigational therapies
Directions to Hospitals Treating Crohn's disease
Risk calculators and risk factors for Crohn's disease future or investigational therapies

Ustekinumab

Recent studies have found that in patients refarctory to treatment with tumor necrosis factor (TNF) antagonists, subcutaneously administered maintenance doses of ustekinumab showed a significant benefit in terms of clinical response but not remission, and were efficacious during a period of 22 weeks.